Symbols / BCLI $0.73 +1.96% Brainstorm Cell Therapeutics Inc.
BCLI Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of Alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Ratings
Current target
$0.73
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-07-11 | up | Maxim Group | Hold → Buy | $2 |
| 2023-09-28 | down | Maxim Group | Buy → Hold | — |
| 2023-03-31 | main | Maxim Group | — → Buy | $10 |
| 2021-02-05 | up | Maxim Group | Hold → Buy | — |
| 2018-05-15 | init | HC Wainwright & Co. | — → Buy | $11 |
| 2017-08-17 | main | Maxim Group | — → Buy | $9 |
- BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update - PR Newswire ue, 31 Mar 2026 07
- Stem cell firm raises $2.4M before Phase 3b ENDURANCE trial - Stock Titan ue, 19 May 2026 12
- BrainStorm Cell Therapeutics posts $2.1M quarterly net loss, cash ~$0.2M as of Mar 31, 2026 - TradingView Fri, 15 May 2026 21
- BrainStorm Cell (OTCQB: BCLI) posts Q1 2026 loss and details NurOwn ALS plans - Stock Titan Fri, 15 May 2026 21
- BrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB - Investing.com hu, 17 Jul 2025 07
- BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire Fri, 14 Nov 2025 08
- BCLI: Focused on Initiation of Phase 3b ENDURANCE Trial of NurOwn® in ALS… - Yahoo Finance Fri, 15 Aug 2025 07
- Brainstorm Cell (BCLI) Q1 2026 loss deepens going-concern pressures - Stock Titan Fri, 15 May 2026 20
- BCLI Stock Price and Chart — OTC:BCLI - TradingView Sat, 19 Jul 2025 18
- Brainstorm Cell Therapeutics Stock Price Forecast. Should You Buy BCLI? - StockInvest.us ue, 01 Dec 2020 12
- What is the current Price Target and Forecast for Brainstorm Cell Therapeutics (BCLI) - Zacks Investment Research Sat, 27 Aug 2022 16
- BCLI SEC Filings - Brainstorm Cell Therapeutics I 10-K, 10-Q, 8-K Forms - Stock Titan Wed, 25 Jun 2025 07
- Brainstorm Cell Therapeuti... (BCLI) Stock News - Stock Titan Mon, 03 Aug 2020 01
- Brainstorm Cell Therapeutics (BCLI) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $BCLI - MarketBeat ue, 08 Jul 2025 07
- Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis $BCLI - MarketBeat Fri, 28 Aug 2015 20
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
9.95
-14.88%
|
11.69
-45.46%
|
21.44
-13.63%
|
24.82
|
| Research And Development |
|
4.17
-10.23%
|
4.65
-56.72%
|
10.75
-23.00%
|
13.96
|
| Selling General And Administration |
|
5.78
-17.95%
|
7.04
-34.14%
|
10.69
-1.59%
|
10.87
|
| General And Administrative Expense |
|
5.78
-17.95%
|
7.04
-34.14%
|
10.69
-1.59%
|
10.87
|
| Other Gand A |
|
5.78
-17.95%
|
7.04
-34.14%
|
10.69
-1.59%
|
10.87
|
| Total Expenses |
|
9.95
-14.88%
|
11.69
-45.46%
|
21.44
-13.63%
|
24.82
|
| Operating Income |
|
-9.95
+14.88%
|
-11.69
+45.46%
|
-21.44
+13.63%
|
-24.82
|
| Total Operating Income As Reported |
|
-9.95
+14.88%
|
-11.69
+45.46%
|
-21.44
+13.63%
|
-24.82
|
| EBITDA |
|
-9.75
+14.83%
|
-11.45
+45.91%
|
-21.17
+13.71%
|
-24.54
|
| Normalized EBITDA |
|
-9.93
+14.37%
|
-11.60
+55.16%
|
-25.87
-5.42%
|
-24.54
|
| Reconciled Depreciation |
|
0.20
-17.08%
|
0.24
-9.43%
|
0.27
-7.02%
|
0.28
|
| EBIT |
|
-9.95
+14.88%
|
-11.69
+45.46%
|
-21.44
+13.63%
|
-24.82
|
| Total Unusual Items |
|
0.18
+21.77%
|
0.15
-96.87%
|
4.69
|
—
|
| Total Unusual Items Excluding Goodwill |
|
0.18
+21.77%
|
0.15
-96.87%
|
4.69
|
—
|
| Net Income |
|
-10.31
+11.32%
|
-11.62
+32.39%
|
-17.19
+29.18%
|
-24.28
|
| Pretax Income |
|
-10.31
+11.32%
|
-11.62
+32.39%
|
-17.19
+29.18%
|
-24.28
|
| Net Non Operating Interest Income Expense |
|
-0.53
-592.21%
|
-0.08
+82.77%
|
-0.45
-182.02%
|
0.55
|
| Net Interest Income |
|
-0.53
-592.21%
|
-0.08
+82.77%
|
-0.45
-182.02%
|
0.55
|
| Interest Income Non Operating |
|
—
|
—
|
—
|
0.55
|
| Interest Income |
|
—
|
—
|
—
|
0.55
|
| Other Income Expense |
|
0.18
+21.77%
|
0.15
-96.87%
|
4.69
|
—
|
| Gain On Sale Of Security |
|
0.18
+21.77%
|
0.15
-96.87%
|
4.69
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-10.31
+11.32%
|
-11.62
+32.39%
|
-17.19
+29.18%
|
-24.28
|
| Net Income From Continuing Operation Net Minority Interest |
|
-10.31
+11.32%
|
-11.62
+32.39%
|
-17.19
+29.18%
|
-24.28
|
| Net Income From Continuing And Discontinued Operation |
|
-10.31
+11.32%
|
-11.62
+32.39%
|
-17.19
+29.18%
|
-24.28
|
| Net Income Continuous Operations |
|
-10.31
+11.32%
|
-11.62
+32.39%
|
-17.19
+29.18%
|
-24.28
|
| Normalized Income |
|
-10.49
+10.91%
|
-11.77
+46.22%
|
-21.89
+9.85%
|
-24.28
|
| Net Income Common Stockholders |
|
-10.31
+11.32%
|
-11.62
+32.39%
|
-17.19
+29.18%
|
-24.28
|
| Diluted EPS |
|
-1.11
+51.95%
|
-2.31
+61.50%
|
-6.00
+39.39%
|
-9.90
|
| Basic EPS |
|
-1.11
+51.95%
|
-2.31
+61.50%
|
-6.00
+39.39%
|
-9.90
|
| Basic Average Shares |
|
9.27
+84.57%
|
5.02
+74.87%
|
2.87
+17.99%
|
2.43
|
| Diluted Average Shares |
|
9.27
+84.57%
|
5.02
+74.87%
|
2.87
+17.99%
|
2.43
|
| Diluted NI Availto Com Stockholders |
|
-10.31
+11.32%
|
-11.62
+32.39%
|
-17.19
+29.18%
|
-24.28
|
| Total Other Finance Cost |
|
0.53
+592.21%
|
0.08
-82.77%
|
0.45
+182.02%
|
-0.55
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1.02
-44.21%
|
1.83
-56.46%
|
4.21
-50.21%
|
8.45
|
| Current Assets |
|
0.31
-20.26%
|
0.39
-79.73%
|
1.90
-38.86%
|
3.11
|
| Cash Cash Equivalents And Short Term Investments |
|
0.03
-84.49%
|
0.19
-85.62%
|
1.30
-56.42%
|
2.98
|
| Cash And Cash Equivalents |
|
0.03
-84.49%
|
0.19
-85.62%
|
1.30
+68.39%
|
0.77
|
| Other Short Term Investments |
|
—
|
—
|
0.00
-100.00%
|
2.21
|
| Receivables |
|
0.09
+36.51%
|
0.06
+23.53%
|
0.05
-43.96%
|
0.09
|
| Other Receivables |
|
0.09
+36.51%
|
0.06
+23.53%
|
0.05
-43.96%
|
0.09
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
0.19
+42.22%
|
0.14
-75.36%
|
0.55
+1612.50%
|
0.03
|
| Total Non Current Assets |
|
0.71
-50.59%
|
1.45
-37.33%
|
2.31
-56.80%
|
5.34
|
| Net PPE |
|
0.44
-64.30%
|
1.24
-40.96%
|
2.10
-60.50%
|
5.32
|
| Accumulated Depreciation |
|
-3.20
-6.63%
|
-3.00
-8.69%
|
-2.76
-10.61%
|
-2.50
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.32
+0.00%
|
0.32
+0.00%
|
0.32
+0.93%
|
0.32
|
| Other Properties |
|
2.48
-19.43%
|
3.08
-16.77%
|
3.70
-44.40%
|
6.66
|
| Leases |
|
0.84
+0.00%
|
0.84
+0.00%
|
0.84
+0.00%
|
0.84
|
| Non Current Prepaid Assets |
|
—
|
—
|
0.02
-4.35%
|
0.02
|
| Other Non Current Assets |
|
0.27
+32.04%
|
0.21
-0.48%
|
0.21
+800.00%
|
0.02
|
| Total Liabilities Net Minority Interest |
|
11.01
+14.70%
|
9.60
+5.85%
|
9.07
-20.93%
|
11.47
|
| Current Liabilities |
|
11.01
+22.60%
|
8.98
+15.10%
|
7.80
-11.36%
|
8.80
|
| Payables And Accrued Expenses |
|
8.43
+20.45%
|
7.00
+13.00%
|
6.19
-1.81%
|
6.31
|
| Payables |
|
8.03
+25.92%
|
6.38
+28.78%
|
4.95
-20.40%
|
6.22
|
| Accounts Payable |
|
7.07
+16.23%
|
6.08
+22.73%
|
4.95
-20.40%
|
6.22
|
| Current Accrued Expenses |
|
0.40
-36.03%
|
0.62
-50.08%
|
1.24
+1376.19%
|
0.08
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.37
+65.66%
|
1.43
+42.57%
|
1.00
-5.82%
|
1.06
|
| Current Debt And Capital Lease Obligation |
|
0.21
-62.11%
|
0.55
-8.96%
|
0.60
-57.74%
|
1.43
|
| Current Capital Lease Obligation |
|
0.21
-62.11%
|
0.55
-8.96%
|
0.60
-57.74%
|
1.43
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
0.62
-51.18%
|
1.27
-52.51%
|
2.67
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
-100.00%
|
0.17
-74.55%
|
0.67
-74.79%
|
2.67
|
| Long Term Capital Lease Obligation |
|
0.00
-100.00%
|
0.17
-74.55%
|
0.67
-74.79%
|
2.67
|
| Stockholders Equity |
|
-9.98
-28.61%
|
-7.76
-59.82%
|
-4.86
-61.13%
|
-3.02
|
| Common Stock Equity |
|
-9.98
-28.61%
|
-7.76
-59.82%
|
-4.86
-61.13%
|
-3.02
|
| Capital Stock |
|
0.02
+14.29%
|
0.01
+7.69%
|
0.01
+8.33%
|
0.01
|
| Common Stock |
|
0.02
+14.29%
|
0.01
+7.69%
|
0.01
+8.33%
|
0.01
|
| Share Issued |
|
11.04
+79.65%
|
6.14
+52.28%
|
4.03
+64.80%
|
2.45
|
| Ordinary Shares Number |
|
11.03
+79.67%
|
6.14
+52.30%
|
4.03
+64.85%
|
2.45
|
| Treasury Shares Number |
|
0.00
+0.00%
|
0.00
+0.06%
|
0.00
+0.00%
|
0.00
|
| Additional Paid In Capital |
|
227.06
+3.69%
|
218.97
+4.15%
|
210.26
+7.87%
|
194.91
|
| Retained Earnings |
|
-236.94
-4.55%
|
-226.64
-5.41%
|
-215.01
-8.69%
|
-197.82
|
| Treasury Stock |
|
0.12
+0.00%
|
0.12
+0.00%
|
0.12
+0.00%
|
0.12
|
| Total Equity Gross Minority Interest |
|
-9.98
-28.61%
|
-7.76
-59.82%
|
-4.86
-61.13%
|
-3.02
|
| Total Capitalization |
|
-9.98
-28.61%
|
-7.76
-59.82%
|
-4.86
-61.13%
|
-3.02
|
| Working Capital |
|
-10.70
-24.52%
|
-8.59
-45.62%
|
-5.90
-3.64%
|
-5.69
|
| Invested Capital |
|
-9.98
-28.61%
|
-7.76
-59.82%
|
-4.86
-61.13%
|
-3.02
|
| Total Debt |
|
0.21
-71.11%
|
0.72
-43.53%
|
1.27
-68.85%
|
4.09
|
| Capital Lease Obligations |
|
0.21
-71.11%
|
0.72
-43.53%
|
1.27
-68.85%
|
4.09
|
| Net Tangible Assets |
|
-9.98
-28.61%
|
-7.76
-59.82%
|
-4.86
-61.13%
|
-3.02
|
| Tangible Book Value |
|
-9.98
-28.61%
|
-7.76
-59.82%
|
-4.86
-61.13%
|
-3.02
|
| Derivative Product Liabilities |
|
0.00
-100.00%
|
0.45
-24.75%
|
0.59
|
0.00
|
| Dueto Related Parties Current |
|
0.97
+222.33%
|
0.30
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-6.97
+23.29%
|
-9.09
+55.55%
|
-20.46
-5.89%
|
-19.32
|
| Cash Flow From Continuing Operating Activities |
|
-6.97
+23.29%
|
-9.09
+55.55%
|
-20.46
-5.89%
|
-19.32
|
| Net Income From Continuing Operations |
|
-10.31
+11.32%
|
-11.62
+32.39%
|
-17.19
+29.18%
|
-24.28
|
| Depreciation Amortization Depletion |
|
0.20
-17.08%
|
0.24
-9.43%
|
0.27
-7.02%
|
0.28
|
| Depreciation |
|
0.20
-17.08%
|
0.24
-9.43%
|
0.27
-7.02%
|
0.28
|
| Depreciation And Amortization |
|
0.20
-17.08%
|
0.24
-9.43%
|
0.27
-7.02%
|
0.28
|
| Stock Based Compensation |
|
1.52
+102.67%
|
0.75
-49.66%
|
1.49
-11.41%
|
1.68
|
| Operating Gains Losses |
|
-0.18
-21.77%
|
-0.15
+96.75%
|
-4.53
|
—
|
| Gain Loss On Investment Securities |
|
-0.18
-21.77%
|
-0.15
+96.75%
|
-4.53
|
—
|
| Change In Working Capital |
|
1.79
+6.22%
|
1.69
+440.12%
|
-0.50
-116.59%
|
2.99
|
| Change In Receivables |
|
—
|
—
|
-0.47
-144.52%
|
1.07
|
| Change In Prepaid Assets |
|
-0.08
-120.70%
|
0.40
+184.42%
|
-0.47
|
—
|
| Change In Payables And Accrued Expense |
|
1.79
+45.13%
|
1.23
+800.00%
|
-0.18
-106.99%
|
2.52
|
| Change In Accrued Expense |
|
0.09
|
0.00
|
—
|
—
|
| Change In Payable |
|
1.70
+38.23%
|
1.23
+800.00%
|
-0.18
-106.99%
|
2.52
|
| Change In Account Payable |
|
0.99
-12.34%
|
1.13
+188.66%
|
-1.27
-150.32%
|
2.52
|
| Change In Other Current Liabilities |
|
0.09
+61.11%
|
0.05
-65.16%
|
0.15
+126.09%
|
-0.59
|
| Investing Cash Flow |
|
0.00
-100.00%
|
0.01
-99.45%
|
2.19
+119.74%
|
1.00
|
| Cash Flow From Continuing Investing Activities |
|
0.00
-100.00%
|
0.01
-99.45%
|
2.19
+119.74%
|
1.00
|
| Net PPE Purchase And Sale |
|
0.00
-100.00%
|
0.01
+166.67%
|
-0.02
+37.93%
|
-0.03
|
| Purchase Of PPE |
|
—
|
—
|
-0.02
+37.93%
|
-0.03
|
| Sale Of PPE |
|
0.00
-100.00%
|
0.01
|
—
|
—
|
| Capital Expenditure |
|
—
|
—
|
-0.02
+37.93%
|
-0.03
|
| Net Investment Purchase And Sale |
|
0.00
|
0.00
-100.00%
|
2.21
+115.29%
|
1.03
|
| Financing Cash Flow |
|
6.88
-13.64%
|
7.97
-58.02%
|
18.98
+7873.95%
|
0.24
|
| Cash Flow From Continuing Financing Activities |
|
6.88
-13.64%
|
7.97
-58.02%
|
18.98
+7873.95%
|
0.24
|
| Net Issuance Payments Of Debt |
|
0.58
|
0.00
|
—
|
—
|
| Issuance Of Debt |
|
0.58
|
0.00
|
—
|
—
|
| Short Term Debt Issuance |
|
0.58
|
0.00
|
—
|
—
|
| Net Short Term Debt Issuance |
|
0.58
|
0.00
|
—
|
—
|
| Net Common Stock Issuance |
|
4.35
-45.44%
|
7.97
-58.02%
|
18.98
+7873.95%
|
0.24
|
| Common Stock Payments |
|
—
|
—
|
—
|
—
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
—
|
| Proceeds From Stock Option Exercised |
|
1.50
|
0.00
|
—
|
0.00
|
| Net Other Financing Charges |
|
0.45
|
—
|
—
|
—
|
| Changes In Cash |
|
-0.10
+91.47%
|
-1.11
-256.24%
|
0.71
+103.94%
|
-18.08
|
| Beginning Cash Position |
|
0.37
-75.02%
|
1.49
+92.36%
|
0.77
-95.91%
|
18.86
|
| End Cash Position |
|
0.28
-25.61%
|
0.37
-75.02%
|
1.49
+92.36%
|
0.77
|
| Free Cash Flow |
|
-6.97
+23.29%
|
-9.09
+55.59%
|
-20.48
-5.82%
|
-19.35
|
| Common Stock Issuance |
|
4.35
-45.44%
|
7.97
-58.02%
|
18.98
+7873.95%
|
0.24
|
| Issuance Of Capital Stock |
|
4.35
-45.44%
|
7.97
-58.02%
|
18.98
+7873.95%
|
0.24
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-05-15 View
- 10-Q2026-05-15 View
- 10-K2026-03-31 View
- 8-K2026-03-31 View
- 8-K2026-02-27 View
- 8-K2026-02-13 View
- 8-K2026-01-09 View
- 10-Q2025-11-14 View
- 8-K2025-11-14 View
- 8-K2025-11-06 View
- 10-Q2025-08-14 View
- 8-K2025-08-14 View
- 8-K2025-07-17 View
- 8-K2025-06-25 View
- 8-K2025-06-16 View
- 8-K2025-05-19 View
- 10-Q2025-05-15 View
- 8-K2025-05-15 View
- 8-K2025-04-21 View
- 10-K2025-03-31 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|